Crescita Therapeutics Inc. (TSX:CTX)
Canada
· Delayed Price · Currency is CAD 0.5700
0.00 (0.00%)
Apr 24, 2025, 12:00 PM EDT
Crescita Therapeutics Revenue
In the year 2024, Crescita Therapeutics had annual revenue of 19.58M CAD with 11.75% growth. Crescita Therapeutics had revenue of 6.90M in the quarter ending December 31, 2024, with 46.07% growth.
Revenue
19.58M
Revenue Growth
+11.75%
P/S Ratio
0.55
Revenue / Employee
n/a
Employees
n/a
Market Cap
10.83M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 19.58M | 2.06M | 11.75% |
| Dec 31, 2023 | 17.52M | -6.00M | -25.52% |
| Dec 31, 2022 | 23.53M | 6.76M | 40.29% |
| Dec 31, 2021 | 16.77M | 1.13M | 7.22% |
| Dec 31, 2020 | 15.64M | -6.70M | -29.98% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Green Thumb Industries | 1.64B |
| dentalcorp Holdings | 1.55B |
| Sienna Senior Living | 893.16M |
| Trulieve Cannabis | 1.71B |
| Extendicare | 1.47B |
| WELL Health Technologies | 919.69M |
| Curaleaf Holdings | 1.93B |
| Cronos Group | 169.23M |
Crescita Therapeutics News
- 5 weeks ago - Crescita Therapeutics GAAP EPS of -C$0.01, revenue of C$6.9M - Seeking Alpha
- 6 months ago - Crescita Reports Third Quarter 2024 Results - Business Wire
- 7 months ago - Crescita Therapeutics Announces Approval of Normal Course Issuer Bid - Business Wire
- 8 months ago - Crescita to Present & Participate in 1x1 Meetings at the Planet MicroCap Showcase: VANCOUVER 2024 in Association with Small Cap Discoveries on Thursday, September 26, 2024 - Business Wire
- 9 months ago - Crescita Therapeutics GAAP EPS of -C$0.05, revenue of C$4.09M - Seeking Alpha
- 9 months ago - Crescita Reports Second Quarter 2024 Results - Business Wire
- 9 months ago - Crescita Secures Contract Manufacturing Revenue of $US10 Million Over 4 Years - Business Wire
- 10 months ago - Leading Canadian Healthcare Services Provider Selects Crescita as Exclusive Manufacturing Partner under 5-Year Agreement - Business Wire